Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …

Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

Purpose Three new oral anticoagulants (NOACs) have recently become available in the
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …

Abstract Background and Objectives Three new oral anticoagulants (NOACs) are currently
approved for stroke prevention and systemic embolism in patients with non-valvular atrial …

Objectives Several direct oral anticoagulants (DOACs) have been approved by the
European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Abstract Background and Objective Evidence indicates that vitamin K antagonists (VKAs)
and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non …

Non‐vitamin K antagonists oral anticoagulants (NOACs) have recently challenged vitamin‐K
antagonists (VKAs) for stroke and systemic embolism prophylaxis in patients with non …

Objectives The primary objective was to assess the cost-effectiveness of new oral
anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation …